ArticleInternational journal of surgery (London, England)2025
TIPS improves survival in patients with cirrhosis and recurrent ascites: a multicenter observational study.
Article in International journal of surgery (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND
aimsCurrently, there is limited evidence regarding the survival benefit of transjugular intrahepatic portal shunt (TIPS) placement in patients with advanced cirrhosis and recurrent ascites. This study aimed to assess whether TIPS improves the survival in such population compared with large volume paracenteses plus albumin (LVP + A).
methodsThis retrospective study included 462 patients with advanced cirrhosis and recurrent ascites who were treated with TIPS (N = 151) or LVP + A (N = 311) at 11 tertiary hospitals in China between September 2014 and September 2020. The Fine and Gray competing risk regression model was used to compare the outcomes between the two groups after adjusting for liver disease severity and other potential confounders.
results1-year overall survival was significantly higher in the TIPS group than in the LVP + A group (77.9% vs 47.3%; P < 0.001), with the relative risk of mortality reduced by 57% (adjusted HR = 0.43, 95% CI: 0.29 to 0.64; P < 0.001). Furthermore, TIPS group had a lower rate of further paracentesis (17.9% vs 100%; P < 0.001) and portal hypertension-related bleeding (5.8% vs 28.1%; P < 0.001) but a higher rate of overt hepatic encephalopathy (26.5% vs 6.4%; P < 0.001) compared with LVP + A group.
conclusionsIn patients with advanced cirrhosis and recurrent ascites, TIPS improved the 1-year survival rates compared with LVP + A. Although TIPS increases the risk of overt hepatic encephalopathy, it can significantly decrease ascites recurrence and portal hypertension-related bleeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.